Dieterich DT, Brunet L, Hsu RK, Mounzer K, Pierone G Jr, Wohlfeiler MB, Fusco, JS, Dunbar MS, Gruber J, Yee LJ, Frenette C, Lim T, Fusco GP. . Monitoring and
risk of hepatitis B reactivation and hepatitis flare during tenofovir interruption among people with HIV and hepatitis B.
, AIDS: 2026
Isobel McEwen1, Gayathri Sridhar2, Richard Elion1, Leigh Ragone3, Annemiek De, Ruiter2, Michael Aboud2, Jean van Wyk4, Kenneth Mayer5, Karam Mounzer6, Moti, N. Ramgopal7, Vani Vannappagari2 Long-Term Use, HIV Testing & Effectiveness in Individuals on CAB LA PrEP
in the Trio Health Cohort , CROI 2026: 2026
Laurence Brunet1, Steven K. Barnett2, Jennifer Fusco3, Karam Mounzer4, Kevin R. Frost5, Supriya Sarkar6, Kimberley Brown7, Harmony P. Garges7, Vani, Vannappagari7, Gregory P. Fusco3 Comparing PrEP Coverage and HIV Acquisition Between CAB LA and Oral
PrEP in the OPERA Cohort , CROI 2026: 2026
Douglas T. Dieterich1, Laurence Brunet2, Ricky K. Hsu3, Karam Mounzer4, Gerald, Pierone5, Michael B. Wohlfeiler6, Rachel P. Weber7, Jennifer Fusco7, Cassidy, Henegar8, Vani Vannappagari9, Kimberley Brown9, Nassrin Payvandi8, Gregory, P. Fusco7 HIV-HBV Coinfection and Long-Acting Cabotegravir + Rilpivirine in the
US: HBV and HIV Outcomes , CROI 2026: 2026
Malcolm Hedgcock1, Mark Bloch2, Jihad Slim3, Moti N. Ramgopal4, Jorge L., Santana5, Xu Zhang6, Jairo M. Montezuma-Rusca6, Peter Sklar6, Karam Mounzer7 Switch to BIC+LEN in Virologically Suppressed People With HIV on
Complex Regimens: Week 96 Outcomes , CROI 2026: 2026
Mohammed Zogheib1, John Koethe2, Karam Mounzer3, John J. Carr2, James G., Terry2, Sangeeta Nair2, Jordan Lake4, Colleen McGary1 Presence of Excess Visceral Abdominal Fat Impacts MASLD in People With
HIV , CROI 2026: 2026
Laurence Brunet1, Ricky K. Hsu2, Anthony Mills3, Kevin R. Frost4, Gerald Pierone5, Michael Sension6, Philip C. Lackey7, Karam Mounzer8, Michael B. Wohlfeiler9, Jennifer Fusco10, Michael Aboud11, Piotr Budnik12, Adrienne Guignard13, Vani, Vannappagari11, Gregory P. Fusco10 Cabotegravir LA for PrEP: Progress in HIV Prevention From 3 Years of OPERA Data , CROI 2026: 2026
Chloe M. Orkin1, Peter J. Ruane2, Malcolm Hedgcock3, Cyril Gaultier4, Marcelo, Losso5, Mark Bloch6, Karam Mounzer7, Hung-Chin Tsai8, Kwanza Price9, Keith, Aizen9, Martin Rhee9, Xu Zhang9, Jairo M. Montezuma-Rusca9, Peter Sklar9, Pedro, Cahn10 Phase III Efficacy and Safety of Switch From Complex Regimen to
Single-Tablet BIC/LEN in ARTISTRY-1 , CROI 2026: 2026
. Wei Y, Ma HK, Wong ME, Back H, Papasavvas E, Mounzer K, Aberra F, , Morgenstern R, Tebas P, Konnikova L, Montaner LJ, Ho YC. Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence. I
, Immunity: 2025
. Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Aizen K, , Zhang X, Sklar P, Montezuma-Rusca JM, Segal-Maurer S . Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline.
, Open Forum Infect Dis
: 2025
